Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.35 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.32 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3606704 | 0.87 | ALDH1A1 (0.35) | SSTR4ALDH1A1CDK1TDP1 | |
| SCHEMBL3606996 | 0.86 | KMT2A (0.39) | CASP1CASP7TSHRL3MBTL1ALDH1A1 | |
| SCHEMBL3610030 | 0.85 | MAPK1 (0.32) | CDK1 | |
| SCHEMBL3599630 | 0.85 | OPRM1 (0.35) | SCN9ACDK1GPR119 | |
| SCHEMBL3604816 | 0.84 | GPR119 (0.36) | SSTR4GPR119PLA2G10PLA2G5 | |
| SCHEMBL3609872 | 0.83 | ALDH1A1 (0.37) | TSHRLMNAL3MBTL1ALDH1A1GAA | |
| SCHEMBL3610736 | 0.82 | ALDH1A1 (0.35) | LMNAALDH1A1GPR119PLA2G10PLA2G5 | |
| SCHEMBL3605596 | 0.79 | ALDH1A1 (0.37) | L3MBTL1ALDH1A1 | |
| SCHEMBL3607457 | 0.78 | USP30 (0.44) | — | |
| SCHEMBL3609805 | 0.78 | ALDH1A1 (0.35) | LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004249-A1 | Bicyclic heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2039695-A1 | BICYCLIC HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-03-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004249-A1 | Bicyclic heterocyclic compound and use thereof | HTR2C, HTR5A, HTR2A | CASP1 1936/4885CASP7 1222/4885TSHR 383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.